版本:
中国

Xenon Pharmaceuticals' acne drug fails mid-stage study

March 24 Xenon Pharmaceuticals Inc said on Friday its drug to treat moderate to severe facial acne failed to meet the primary goal in a mid-stage study.

The drug, XEN801, which was tested against a placebo, did not induce a statistically significant effect on total lesion count, the company said. (Reporting by Divya Grover in Bengaluru; Editing by Martina D'Couto)

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐